CRISPR/Cas9-Mediated Knockout of Lcn2 in Human Breast Cancer Cell Line MDA-MB-231 Ameliorates Erastin-Mediated Ferroptosis and Increases Cisplatin Vulnerability

Scientists abrogated lipocalin 2 (Lcn2) expression in MDA-MB-231 breast cancer cells using the CRISPR/Cas9 technology and evaluated its effect on cellular proliferation, migration, and ferroptotic cell death.